Oriana et. al., supplementary information

## Synthesis of tri-functionalized MMP2 FRET probes using a chemoselective and late-stage modification of unprotected peptides

# -supporting information-

Sean Oriana, Ye Cai, Jeffrey W. Bode, and Yoko Yamakoshi\* Laboratorium für Organische Chemie, ETH-Zürich, Vladimir-Prelog-Weg 3, CH8093 Zürich, Switzerland

# **1.** Synthesis of ketoacid derivative of methoxylcounarin and hydroxylamine Lys deriveative



**Fig. S1** <sup>1</sup>H-NMR spectrum of compound **4** (in CDCl<sub>3</sub>, 400 MHz).



Fig. S2 <sup>13</sup>C-NMR spectrum of compound 4 (in CDCl<sub>3</sub>, 100 MHz).



Fig. S3 <sup>19</sup>F-NMR spectrum of compound 4 (in CDCl<sub>3</sub>, 377 MHz).



**Fig. S5** <sup>1</sup>H NMR spectrum of compound **2** (in  $CDCl_3$ , 600 MHz).



Fig. S6 <sup>13</sup>C NMR spectrum of compound 2 (in CDCl<sub>3</sub>, 150 MHz).



Fig. S7 <sup>19</sup>F NMR spectrum of compound 2 (in CDCl<sub>3</sub>, 377 MHz).









**Fig. S9** <sup>1</sup>H-NMR spectrum of compound **7** (in CDCl<sub>3</sub>, 400 MHz).



**Fig. S10** <sup>13</sup>C-NMR spectrum of compound **7** (in CDCl<sub>3</sub>, 100 MHz).



Fig. S11 IR spectrum of compound 7.





Fig. S12 <sup>1</sup>H-NMR spectrum of compound 8 (in CDCl<sub>3</sub>, 400 MHz).



Fig. S13 <sup>13</sup>C-NMR spectrum of compound 8 (in CDCl<sub>3</sub>, 100 MHz).



Fig. S15 <sup>1</sup>H-NMR spectrum of compound 9 (in CDCl<sub>3</sub>, 400 MHz).



**Fig. S16** <sup>13</sup>C-NMR spectrum of compound **9** (in CDCl<sub>3</sub>, 100 MHz).



Fig. S17 IR spectrum of compound 9



**Fig. S18** <sup>1</sup>H-NMR spectrum of compound **10** (in CDCl<sub>3</sub>, 400 MHz).



Fig. S19<sup>13</sup>C-NMR spectrum of compound 10 (in CDCl<sub>3</sub>, 100 MHz).



Fig. S20 IR spectrum of compound 10.



Fig. S21 <sup>1</sup>H-NMR spectrum of compound 1 (in CDCl<sub>3</sub>, 400 MHz).



**Fig. S22** Expanded <sup>13</sup>C-NMR spectrum of compound **1** (in CDCl<sub>3</sub>, 100 MHz).



Fig. S23 IR spectrum of compound 1



#### 2. Test KAHA reaction of 4 and 9

**Fig. S25** ESI mass spectra of peaks with retention time at (a) 4.4 (m/z 608, corresponding to [M+H] of 11), (b) 4.9 (m/z 529, corresponding to [M+H] of 9.

### 3. Solid phase peptide synthesis (SPPS)



**Fmoc-GABA-Gly-Pro-Leu-Gly-Val-Arg(Pbf)-Gly-Cys(Trt)-Ala-NH<sub>2</sub> on MBHA rink amide resin12.** 



Fig. S26 MALDI spectrum of crude compound 12 (Matrix: HCCA)



Fmoc-Lys(OBz)-GABA-Gly-Pro-Leu-Gly-Val-Arg(Pbf)-Gly-Cys(Trt)-Ala-NH<sub>2</sub> on MBHA rink amide resin 13.



Fig. S27 MALDI spectrum of crude compound 13 (Matrix: HCCA)



MPEG<sub>12</sub>-Fmoc-Lys(OBz)Boc-GABA-Gly-Pro-Leu-Gly-Val-Arg(Pbf)-Gly-Cys(Trt)-Ala-NH<sub>2</sub> on MBHA rink amide resin 14.



Fig. S28 MALDI spectrum of crude compound 14 (Matrix: HCCA)



MPEG<sub>12</sub>-Fmoc-Lys(OBz)-GABA-Gly-Pro-Leu-Gly-Val-Arg-Gly-Cys-Ala-NH<sub>2</sub> 15.



Fig. S29 MALDI-TOF-MS spectrum of compound 15 purified by HPLC (Matrix: HCCA)

4. Peptide modification with FRET acceptor, donor, and polymer



MPEG<sub>12</sub>-Fmoc-Lys(MC)-GABA-Gly-Pro-Leu-Gly-Val-Arg-Gly-Cys-Ala-NH<sub>2</sub> 16.



Fig. S30 MALDI spectrum of HPLC purified compound 16 (Matrix: HCCA)



MPEG<sub>12</sub>-Fmoc-Lys(MC)-GABA-Gly-Pro-Leu-Gly-Val-Arg-Gly-Cys(DNP)-Ala-NH<sub>2</sub> Probe A 17.



Fig. S31 Analytical HPLC trace of purified compound 17 (probe A) at 220 nm.



Fig. S32 High resolution MALDI spectrum of purified compound 17 (probe A).





Fig. S33 Analytical HPLC trace of purified probe B at 220 nm.



Fig. S34 High resolution MALDI spectrum of purified probe B.

(MALDI-TOF *m*/*z* calcd. 2219.0788 for  $C_{98}H_{156}N_{21}O_{35}S$ , found 2219. 0797 ([M+H]<sup>+</sup>) S18/S23

#### 5. Enzyme test using MMP2

#### Probe A

### $MPEG_{12}\mbox{-}Fmoc\mbox{-}Lys(MC)\mbox{-}GABA\mbox{-}Gly\mbox{-}Pro\mbox{-}Leu\mbox{-}Gly\mbox{-}Val\mbox{-}Arg\mbox{-}Gly\mbox{-}Cys(DNP)\mbox{-}Ala\mbox{-}NH_2$

#### Probe B

## $MPEG_{12}\mbox{-}Fmoc\mbox{-}Lys(MC)\mbox{-}GABA\mbox{-}Gly\mbox{-}Val\mbox{-}Arg\mbox{-}Leu\mbox{-}Gly\mbox{-}Pro\mbox{-}Gly\mbox{-}Cys(DNP)\mbox{-}Ala\mbox{-}NH_2$

| <b>Table S1.</b> Reaction set up for Enzyme cleavage experiment |           |      |           |                               |                       |
|---|-----------|------|-----------|-------------------------------|-----------------------|
| run   | Substrate | MMP2 | Inhibitor | Reaction time [min]           | Reaction time [min]   |
|   |           |      |           | (MS spectra)                  | (fluorescent spectra) |
| R1  | probe A   | _    | _         | 0, 120, 200 min (Fig. S35a-c) | 0, 240 min (Fig. S42) |
| R2  | probe A   | +    | _         | 0, 120, 200 min (Fig. S36a-c) | 240 min (Fig. S43)    |
| R3  | probe A   | +    | +         | 0, 120, 200 min (Fig. S37a-c) | 240 min (Fig. S44)    |
| R4  | probe B   | _    | _         | 0, 120, 200 min (Fig. S38a-c) | 0, 240 min (Fig. S45) |
| R5  | probe B   | +    | _         | 0, 120, 200 min (Fig. S39a-c) | 240 min (Fig. S46)    |
| R6  | probe B   | +    | +         | 0, 120, 200 min (Fig. S40a-c) | 240 min (Fig. S47)    |







Fig. S36 MALDI-TOF-MS spectra of R2 (a) 0 min, (b) 120 min, (c) 200 min.



Fig. S37 MALDI-TOF-MS spectra of R3 (a) 0 min, (b) 120 min, (c) 200 min.



Fig. S38 MALDI-TOF-MS spectra of R4 (a) 0 min, (b) 120 min, (c) 200 min.



Fig. S39 MALDI-TOF-MS spectra of R5 (a) 0 min, (b) 120 min, (c) 200 min.



Fig. S40 MALDI-TOF-MS spectra of R6 (a) 0 min, (b) 120 min, (c) 200 min.



Fig. S41 Overlaid Fluorescence Spectra of R1-R6 (4 hr)





